Skip to content

Mesa Laboratories MLAB Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

ICU Medical logo
ICU MedicalICUI
Myriad Genetics logo
Myriad GeneticsMYGN

Other financials

Income statement

See full
Revenue$63.7M+2.6%
Gross profit$31.2M-0.5%
Operating income-$664.0K+85.5%
Net income$3.6M+317%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$26.9M-1.4%
Total debt$78.7M-53.1%
Total equity$186.2M+16.5%
Total assets$427.7M-1.3%

Cash flow

See full
Operating cash flow$14.0M+10.2%
CapEx$417.0K-44.9%
Free cash flow$13.5M+13.7%

Valuation

See full
Market cap$542.27M+3.7%
Enterprise value$594.05M-10.4%
P/S2.2×0.0×

Profitability

See full
Gross margin56.8%
Operating margin2.3%
Net margin1.5%+0.8pp
FCF margin15.9%-1.8pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.6×
Current ratio1.7×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mesa Laboratories's payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mesa Laboratories's payments to acquire intangible assets?
Mesa Laboratories (MLAB) reported payments to acquire intangible assets of -$0 in Q1 2026.
How has Mesa Laboratories's payments to acquire intangible assets changed year-over-year?
Mesa Laboratories's payments to acquire intangible assets decreased by 100.0% year-over-year, from $62.5K to -$0.